Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles.
Mitoxantrone, an antineoplastic anthracycline antibiotic with a wide range of veterinary applications, was developed as a less cardiotoxic alternative to doxorubicin, a related compound in this family of chemotherapy agents. Mitoxantrone has not gained widespread acceptance in the veterinary community, primarily due to its cost and single-dose packaging in a volume that exceeds the needs of the majority of veterinary cancer patients. The in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles was evaluated to determine whether long-term storage at -20 degrees C resulted in decreased efficacy. The drug was frozen between treatment cycles to minimize the risk of bacterial contamination because it is supplied as a preservative-free solution. Results indicated mitoxantrone maintained its cytotoxicity against cancer cells in culture following multiple freeze-thaw cycles spanning at least 12 months.
Mauldin
G Neal
GN
Louisiana State University, School of Veterinary Medicine, Veterinary Clinical Sciences, Baton Rouge, LA 70803, USA.
Truax
Robert
R
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D005615:Freezing; D008545:Melanoma / Q000473:pathology; D008942:Mitoxantrone / Q000737:chemistry* / Q000494:pharmacology*; D013696:Temperature; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D008942:Mitoxantrone